Solid Biosciences Inc. (NASDAQ:SLDB), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per share.
Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000.
Solid Biosciences is a life science company focused on solving Duchenne muscular dystrophy. We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted by Duchenne muscular dystrophy, our mandate is simple yet comprehensive – attack the roots of the disease and improve daily life for patients.